Friday, January 09, 2015 11:54:10 PM
Probably should'a just stopped at that:
It's going to be an interesting ride if half of what some here anticipate is going to happen,... does happen.
Speculate for just a second - even if just to yourself,...
If come July 2015,....
The now NNVC-Owned Shelton plant has successfully scaled up to regular Kg-scale syntheses of 'Cides,...
TOX is nearly completed, if not to be completed within a couple of months,...
An Ebolacide compound (or set of them) has been identified that can give obvious advantages in Mice and Primate models against Ebola,....
Or more,...
What is the trading sharprice here likely to be?
At the very least - it could be a "helluva" first half of 2015. And I like our odds at getting at least 2 of these 3, and quite possibly all 3 of these done by then.
:D
it will be a "helluva" first half of 2015
It's going to be an interesting ride if half of what some here anticipate is going to happen,... does happen.
Speculate for just a second - even if just to yourself,...
If come July 2015,....
The now NNVC-Owned Shelton plant has successfully scaled up to regular Kg-scale syntheses of 'Cides,...
TOX is nearly completed, if not to be completed within a couple of months,...
An Ebolacide compound (or set of them) has been identified that can give obvious advantages in Mice and Primate models against Ebola,....
Or more,...
What is the trading sharprice here likely to be?
At the very least - it could be a "helluva" first half of 2015. And I like our odds at getting at least 2 of these 3, and quite possibly all 3 of these done by then.
:D
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
